22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Clinical News

AAV1-FS344: Phase I/IIa data

A dose-escalation Phase I/IIa trial in 6 patients with Becker muscular dystrophy showed that AAV1-FS344 given by direct bilateral intramuscular quadriceps injections improved 6MWT in 4 patients. In cohort 1 (n=3), 3*1011 vg/kg/leg AAV1-FS344 improved...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

AAV1-FS344 regulatory update

Milo said FDA granted Orphan Drug designation to AAV1-FS344 to treat Becker and Duchenne muscular dystrophy. The adeno-associated virus (AAV) vector encoding follistatin is in a Phase I/II trial for Becker muscular dystrophy and inclusion...
07:00 , Aug 6, 2012 |  BioCentury  |  Emerging Company Profile

Milo: Dismissing dystrophin

Milo Biotechnology LLC is developing a gene therapy to treat muscular dystrophy that up-regulates follistatin, a protein already present in the body, which could avoid immune reactions that have scuttled previous gene therapies. The company's only...
01:40 , Feb 17, 2012 |  BC Extra  |  Company News

Newco Milo debuts to develop muscular dystrophy treatment

Milo Biotechnology LLC (Cleveland, Ohio) raised $250,000 in seed funding from the not-for-profit JumpStart Inc. The newco's lead product, AAV1-FS, is an adeno-associated virus (AAV) vector used to deliver follistatin. Follistatin is a protein that...